文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

机械扩张与自膨胀经导管主动脉瓣置换术在高危主动脉瓣狭窄患者中的比较:REPRISE III随机临床试验

Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

REPRISE III试验在912例高危或极高危重度症状性主动脉瓣狭窄患者中比较机械扩张瓣膜(MEV)与自膨胀瓣膜(SEV)行TAVR的安全性和有效性。30天主要安全复合终点MEV组20.3% vs SEV组17.2%,达到非劣效;1年主要有效性复合终点MEV组15.4% vs SEV组25.5%,达到非劣效并显示优效。MEV组新起搏器植入率和瓣膜血栓率更高,但重复操作、瓣中瓣植入和瓣膜错位率更低。

要点

  • MEV组30天主要安全复合终点20.3%,SEV组17.2%,差异3.1%,达到非劣效。
  • MEV组1年主要有效性复合终点15.4%,SEV组25.5%,达到非劣效并显示优效。
  • MEV组新起搏器植入率35.5%高于SEV组19.6%,瓣膜血栓1.5%高于SEV组0%。

核心结论

  • 在高危主动脉瓣狭窄患者中,与SEV相比,MEV在主要安全终点和主要有效性终点上均未产生劣于SEV的结果。
  • MEV可能为高危患者TAVR提供一种有用的补充选择。

研究设计与样本

  • REPRISE III为随机临床试验,在北美、欧洲和澳大利亚55个中心开展。
  • 2014年9月22日至2015年12月24日纳入912例高危或极高危重度症状性主动脉瓣狭窄患者,按2:1随机分配至MEV组(n=607)或SEV组(n=305)。
  • 患者平均年龄82.8岁(SD 7.3),女性463例(51%),预测死亡风险6.8%;874例(96%)在1年时可评估。

主要发现

  • 30天主要安全复合终点(全因死亡、卒中、危及生命或大出血、2/3期急性肾损伤、主要血管并发症)MEV组20.3% vs SEV组17.2%,差异3.1%(Farrington-Manning 97.5% CI,-∞至8.3%;非劣效P=.003)。
  • 1年主要有效性复合终点(全因死亡、致残性卒中、中度或以上瓣周漏)MEV组15.4% vs SEV组25.5%,差异-10.1%(Farrington-Manning 97.5% CI,-∞至-4.4%;非劣效P<.001)。
  • 1年中度或重度瓣周漏MEV组0.9% vs SEV组6.8%,差异-6.1%(95% CI,-9.6%至-2.6%;P<.001)。
  • 主要有效性优效性分析差异-10.2%(95% CI,-16.3%至-4.0%;P<.001)。
  • MEV组新起搏器植入率35.5% vs SEV组19.6%(P<.001),瓣膜血栓1.5% vs 0%;MEV组重复操作0.2% vs SEV组2.0%,瓣中瓣植入0% vs 3.7%,瓣膜错位0% vs 2.7%。

关键数值与推荐

  • 主要安全终点非劣效界值10.5%,主要有效性终点非劣效界值9.5%。
  • 若满足非劣效,则在全分析集中对1年中度或以上瓣周漏进行优效性检验。

临床怎么用

  • 在高危主动脉瓣狭窄患者TAVR中,MEV在主要安全性和有效性终点上不劣于SEV,可作为瓣膜选择的一种参考。
  • 选择MEV时应关注其较高的新起搏器植入率和瓣膜血栓发生率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transcatheter aortic valve replacement (TAVR) is established for selected patients with severe aortic stenosis. However, limitations such as suboptimal deployment, conduction disturbances, and paravalvular leak occur. OBJECTIVE: To evaluate if a mechanically expanded valve (MEV) is noninferior to an approved self-expanding valve (SEV) in high-risk patients with aortic stenosis undergoing TAVR. DESIGN, SETTING, AND PARTICIPANTS: The REPRISE III trial was conducted in 912 patients with high or extreme risk and severe, symptomatic aortic stenosis at 55 centers in North America, Europe, and Australia between September 22, 2014, and December 24, 2015, with final follow-up on March 8, 2017. INTERVENTIONS: Participants were randomized in a 2:1 ratio to receive either an MEV (n = 607) or an SEV (n = 305). MAIN OUTCOMES AND MEASURES: The primary safety end point was the 30-day composite of all-cause mortality, stroke, life-threatening or major bleeding, stage 2/3 acute kidney injury, and major vascular complications tested for noninferiority (margin, 10.5%). The primary effectiveness end point was the 1-year composite of all-cause mortality, disabling stroke, and moderate or greater paravalvular leak tested for noninferiority (margin, 9.5%). If noninferiority criteria were met, the secondary end point of 1-year moderate or greater paravalvular leak was tested for superiority in the full analysis data set. RESULTS: Among 912 randomized patients (mean age, 82.8 [SD, 7.3] years; 463 [51%] women; predicted risk of mortality, 6.8%), 874 (96%) were evaluable at 1 year. The primary safety composite end point at 30 days occurred in 20.3% of MEV patients and 17.2% of SEV patients (difference, 3.1%; Farrington-Manning 97.5% CI, -∞ to 8.3%; P = .003 for noninferiority). At 1 year, the primary effectiveness composite end point occurred in 15.4% with the MEV and 25.5% with the SEV (difference, -10.1%; Farrington-Manning 97.5% CI, -∞ to -4.4%; P<.001 for noninferiority). The 1-year rates of moderate or severe paravalvular leak were 0.9% for the MEV and 6.8% for the SEV (difference, -6.1%; 95% CI, -9.6% to -2.6%; P < .001). The superiority analysis for primary effectiveness was statistically significant (difference, -10.2%; 95% CI, -16.3% to -4.0%; P < .001). The MEV had higher rates of new pacemaker implants (35.5% vs 19.6%; P < .001) and valve thrombosis (1.5% vs 0%) but lower rates of repeat procedures (0.2% vs 2.0%), valve-in-valve deployments (0% vs 3.7%), and valve malpositioning (0% vs 2.7%). CONCLUSIONS AND RELEVANCE: Among high-risk patients with aortic stenosis, use of the MEV compared with the SEV did not result in inferior outcomes for the primary safety end point or the primary effectiveness end point. These findings suggest that the MEV may be a useful addition for TAVR in high-risk patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02202434.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial. JAMA. 2018. PMID: 29297076. doi:10.1001/jama.2017.19132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。